Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion

Authors: Niina M Santio, Riitta L Vahakoski, Eeva-Marja Rainio, Jouko A Sandholm, Sanna S Virtanen, Michelle Prudhomme, Fabrice Anizon, Pascale Moreau, Päivi J Koskinen

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Pim family kinases are small constitutively active serine/threonine-specific kinases, elevated levels of which have been detected in human hematopoietic malignancies as well as in solid tumours. While we and others have previously shown that the oncogenic Pim kinases stimulate survival of hematopoietic cells, we now examined their putative role in regulating motility of adherent cancer cells. For this purpose, we inhibited Pim kinase activity using a small molecule compound, 1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde (DHPCC-9), which we had recently identified as a potent and selective inhibitor for all Pim family members.

Results

We now demonstrate that the Pim kinase inhibitor DHPCC-9 is very effective also in cell-based assays. DHPCC-9 impairs the anti-apoptotic effects of Pim-1 in cytokine-deprived myeloid cells and inhibits intracellular phosphorylation of Pim substrates such as Bad. Moreover, DHPCC-9 slows down migration and invasion of cancer cells derived from either prostate cancer or squamocellular carcinoma patients. Silencing of Pim expression reduces cell motility, while Pim overexpression enhances it, strongly suggesting that the observed effects of DHPCC-9 are dependent on Pim kinase activity. Interestingly, DHPCC-9 also abrogates NFATc-dependent migration of cancer cells, implying that NFATc factors mediate at least part of the pro-migratory effects of Pim kinases.

Conclusions

Altogether, our data indicate that DHPCC-9 is not only a powerful tool to investigate physiological effects of the oncogenic Pim family kinases, but also an attractive molecule for drug development to inhibit invasiveness of Pim-overexpressing cancer cells.
Appendix
Available only for authorised users
Literature
1.
Eichmann A, Yuan L, Bréant C, Alitalo K, Koskinen PJ: Developmental expression of Pim kinases suggests functions also outside of the hematopoietic system. Oncogene. 2000, 19: 1215-1224. 10.1038/sj.onc.1203355CrossRefPubMed
2.
Mikkers H, Nawijn M, Allen J: Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol. 2004, 24: 6104-6115. 10.1128/MCB.24.13.6104-6115.2004PubMedCentralCrossRefPubMed
3.
Qian KC, Wang L, Hickey ER: Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem. 2005, 280: 6130-6137. 10.1074/jbc.M409123200CrossRefPubMed
4.
Dautry F, Weil D, Yu J, Dautry VA: Regulation of pim and myb mRNA accumulation by interleukin 2 and interleukin 3 in murine hematopoietic cell lines. J Biol Chem. 1988, 263: 17615-17620.PubMed
5.
Lilly M, Le T, Holland P, Hendrickson SL: Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. Oncogene. 1992, 7: 727-732.PubMed
6.
Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I: Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Rα, c-myc, and pim-1 genes in human T cells. Blood. 1999, 93 (6): 1980-1991.PubMed
7.
van Lohuizen M, Verbeek S, Krimpenfort P: Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell. 1989, 56: 673-682. 10.1016/0092-8674(89)90589-8CrossRefPubMed
8.
Möröy T, Verbeek S, Ma A, Achacoso P, Berns A, Alt F: Eμ N- and Eμ L-myc cooperate with Eμ pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice. Oncogene. 1991, 6: 1941-1948.PubMed
9.
Acton D, Domen J, Jacobs H, Vlaar M, Korsmeyer S, Berns A: Collaboration of pim-1 and bcl-2 in lymphomagenesis. Curr Top Microbiol Immunol. 1992, 182: 293-298.PubMed
10.
Schmidt T, Karsunky H, Gau E, Zevnik B, Elsasser HP, Moroy T: Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis. Oncogene. 1998, 17: 2661-2667. 10.1038/sj.onc.1202191CrossRefPubMed
11.
Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A: The human protooncogene product p33 pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA. 1989, 86: 8857-8861. 10.1073/pnas.86.22.8857PubMedCentralCrossRefPubMed
12.
Shah N, Pang B, Yeoh KG: Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur J Cancer. 2008, 44: 2144-2151. 10.1016/j.ejca.2008.06.044CrossRefPubMed
13.
Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J: PIM serine/threonine kinases in pathogenesis and therapy of hematological malignancies and solid cancers. Haematologica. 2010, 95: 1004-1015. 10.3324/haematol.2009.017079PubMedCentralCrossRefPubMed
14.
Bachmann M, Möröy T: The serine/threonine kinase Pim-1. Int J Biochem Cell Biol. 2005, 37: 726-730. 10.1016/j.biocel.2004.11.005CrossRefPubMed
15.
Leverson JD, Koskinen PJ, Orrico FC: Pim-1 kinase and p100 cooperate to enhance c-Myb activity. Mol Cell. 1998, 2: 417-425. 10.1016/S1097-2765(00)80141-0CrossRefPubMed
16.
Rainio EM, Sandholm J, Koskinen PJ: Cutting edge: Transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J Immunol. 2002, 168: 1524-1527.CrossRefPubMed
17.
Aho TLT, Sandholm J, Peltola KJ, Ito Y, Koskinen PJ: Pim-1 kinase phosphorylates RUNX family transcription factors and enhances their activity. BMC Cell Biol. 2006, 7: 21- 10.1186/1471-2121-7-21PubMedCentralCrossRefPubMed
18.
Yan B, Zemskova M, Holder S: The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003, 278: 45358-45367. 10.1074/jbc.M307933200CrossRefPubMed
19.
Aho TLT, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ: Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004, 571: 43-49. 10.1016/j.febslet.2004.06.050CrossRefPubMed
20.
Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ, Arthur JS: Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol. 2006, 7: 1-14. 10.1186/1471-2121-7-1PubMedCentralCrossRefPubMed
21.
Akué-Gédu R, Rossignol E, Azzaro S: Synthesis, kinase Inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. J Med Chem. 2009, 52: 6369-6381. 10.1021/jm901018fCrossRefPubMed
22.
Holder S, Zemskova M, Zhang C: Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther. 2007, 6: 163-6172. 10.1158/1535-7163.MCT-06-0397CrossRefPubMed
23.
Pogacic V, Bullock AN, Fedorov O: Structural analysis identifies imidazo[1, 2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res. 2007, 67: 6916-6924. 10.1158/0008-5472.CAN-07-0320CrossRefPubMed
24.
Xia Z, Knaak C, Ma J: Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009, 52: 74-86. 10.1021/jm800937pCrossRefPubMed
25.
Tao ZF, Hasvold LA, Leverson JD: Discovery of 3H-benzo[4, 5]thieno[3, 2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases. J Med Chem. 2009, 52: 6621-6636. 10.1021/jm900943hCrossRefPubMed
26.
Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V: Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2009, 114: 4150-4157. 10.1182/blood-2009-03-212852PubMedCentralCrossRefPubMed
27.
Mumenthaler SM, Ng PY, Hodge A: Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009, 8: 2882-2893. 10.1158/1535-7163.MCT-09-0293PubMedCentralCrossRefPubMed
28.
Lilly M, Sandholm J, Cooper JJ, Koskinen PJ, Kraft A: The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene. 1999, 18: 4022-4031. 10.1038/sj.onc.1202741CrossRefPubMed
29.
Peltola K, Hollmen M, Maula SM: Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia. 2009, 11: 629-636.PubMedCentralCrossRefPubMed
30.
Mosmann T: Rapid colorimetric assay for cell growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983, 65: 55-63. 10.1016/0022-1759(83)90303-4CrossRefPubMed
31.
Li M, Zhang Z, Hill DL, Chen X, Wang H, Zhang R: Genistein, a dietary isoflavone, downregulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res. 2005, 65: 8200-8208. 10.1158/0008-5472.CAN-05-1302CrossRefPubMed
32.
Jauliac S, López-Rodriques C, Shaw L, Brown L, Rao A, Toker A: The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol. 2002, 4: 540-544. 10.1038/ncb816CrossRefPubMed
33.
Qian K, Wang L, Cywin CL: Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. J Med Chem. 2009, 52: 1814-1827. 10.1021/jm801242yCrossRefPubMed
34.
Bullock AN, Debreczeni JE, Fedorov OY, Nelson A, Marsden B, Knapp S: Structural Basis of Inhibitor Specificity of the Human Protooncogene Proviral Insertion Site in Moloney Murine Leukemia Virus (PIM-1) Kinase. J Med Chem. 2005, 48: 7604-7614. 10.1021/jm0504858CrossRefPubMed
35.
Zemskova M, Sahakian E, Bashkirova S, Lilly M: The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of doxotacel-treated prostate cancer cells. J Biol Chem. 2008, 283: 20635-20644. 10.1074/jbc.M709479200PubMedCentralCrossRefPubMed
36.
37.
Zhang P, Wang H, Min X: Pim-3 is expressed in endothelial cells and promotes vascular tube formation. J Cell Physiol. 2009, 220 (1): 82-90. 10.1002/jcp.21733CrossRefPubMed
38.
Grundler R, Brault L, Gasser C: Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med. 2009, 206: 1957-1970. 10.1084/jem.20082074PubMedCentralCrossRefPubMed
39.
Metadata
Title
Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion
Authors
Niina M Santio
Riitta L Vahakoski
Eeva-Marja Rainio
Jouko A Sandholm
Sanna S Virtanen
Michelle Prudhomme
Fabrice Anizon
Pascale Moreau
Päivi J Koskinen
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-279

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection

Research

Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells

Research

Serum N-glycome biomarker for monitoring development of DENA-induced hepatocellular carcinoma in rat

Research

Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion

Research

Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations

Research

ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARα -mediated inhibition of Glioma cell motility in vitro
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits